Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze GMED Globus Medical, Inc.: https://finlab.finance/en/setup?stock=GMED”

Run AI in browser

GMED

Globus Medical, Inc. Healthcare As of 2026-06-18

Quality Above avg

Valuation Expensive

Risk Moderate

Active signals Active Filed revenue acceleration

79.23 Close (USD)

-8.14% 60-day

Quality is above average. Operating margin sits near the 70th percentile. TTM ROE is about 12.4%.
Valuation is expensive. TTM P/E is in the 72th percentile, above most peers.
Recent volatility is moderate. 60-day annualized volatility is near the 58th percentile. Average 20-day dollar volume is about $144.5M.
Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Factor profile

Factor radar Neutral Valuation

Valuation

Indicators in this group are ranked by market percentile; lower valuation and volatility are better.

44 Neutral

TTM P/E 18.51

Pricey

Price / book 2.27

Pricey

Free-cash-flow yield (%) 5.64

Good

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 23.491343431004342%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

11 historical occurrences (since 2018-08-02)

120 days after: historical avg +4.21%

20-day +0.81%

60-day +3.91%

120-day +4.21%

20-day

60-day

120-day

Win

36.4%

60%

44.4%

Sample

Median

-2.45%

+2.24%

-7.01%

Excess

-1.5%

-1.18%

-1.45%

Beat mkt rate

18.2%

30%

33.3%

Over 9 occurrences, 120-day forward avg gained 4.21%, lagged the market by 1.45 pts; win rate 44.4%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

0-20 +29.9% Now

20-40 +35.3%

40-60 +18.9%

60-80 -0.5%

80-100 +3.3%

PE percentile band	Sample days	240-day avg return	Median	Win rate	Avg excess (vs index)
0-20 You are here	149	+29.9%	+29.1%	89.3%	0%
20-40	114	+35.3%	+40.8%	79.8%	+9.4%
40-60	192	+18.9%	+7.1%	65.1%	+3.9%
60-80	331	-0.5%	-12.6%	35.3%	-6%
80-100	548	+3.3%	+3.1%	54%	-11.2%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 18.51, placing it in the 0.6 own-history percentile, inside the 0-20 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation

Momentum

Cheap (own-history bottom third)

Middle

Expensive (own-history top third)

60-day momentum up

+10%

Win rate 37.8% Excess +3.3%

127d

+17.6%

Win rate 67.5% Excess +6.1%

114d

+1.4%

Win rate 53.4% Excess -5.6%

596d

60-day momentum down

Now

+11.9%

Win rate 62.5% Excess -2%

184d

+15.4%

Win rate 60% Excess +12.1%

255d

+5.3%

Win rate 50% Excess -2.9%

176d

Currently in “Cheap (own-history bottom third) × 60-day momentum down”: across 184 historical days, 120-day forward avg gained 11.9%, win rate 62.5%, lagged the market by 2%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 94,737 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.40%, a 58.3% positive-return rate, and +3.10 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

22 times historically; 60-day forward avg +2.54%, win rate 66.7%, beating the market by +0.37 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

17 times historically; 60-day forward avg -0.72%, win rate 52.9%, beating the market by -2.66 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

28 times historically; 60-day forward avg +4.11%, win rate 58.3%, beating the market by +0.83 pts on average.

Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze GMED Globus Medical, Inc.: https://finlab.finance/en/setup?stock=GMED”

Run AI in browser

Method and limits

Returns use us_price:adj_close, adjusted for splits and dividends where available.
Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.